Live attenuated bacteria as vectors to deliver plasmid DNA vaccines

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 1, 2003, Pages 10-19

  Dietrich, Guido ^a   Spreng, Simone ^a   Favre, Didier ^a   Viret, Jean François ^a   Guzman, Carlos Alberto ^b  

^a Berna Biotech AG   (Switzerland)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

DNA vaccine delivery; DNA vaccines; Live bacterial vaccines; Mucosal vaccination

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIBODY; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; INTERLEUKIN 2; LIVE VACCINE; NAKED DNA; PLASMID DNA; VASCULOTROPIN RECEPTOR 2;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BACTERIAL INFECTION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXPRESSION VECTOR; FIBROSARCOMA; GENE DELIVERY SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; KIDNEY CARCINOMA; LISTERIA; LUNG ADENOCARCINOMA; MELANOMA; MICROBIAL ATTENUATION; NEUROBLASTOMA; NONHUMAN; REVIEW; SALMONELLA; SALMONELLA ENTERICA; SHIGELLA; STRAIN DIFFERENCE; VACCINATION; VIBRIO CHOLERAE; VIRUS INFECTION;

ANIMALS; BACTERIA; BACTERIAL VACCINES; CANCER VACCINES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; PLASMIDS; VACCINES, ATTENUATED; VACCINES, DNA;

ANIMALIA; BACTERIA (MICROORGANISMS); EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS; LISTERIA; SALMONELLA; SALMONELLA ENTERICA; SHIGELLA; VECTORS; VIBRIO; VIBRIO CHOLERAE;

EID: 0037299739     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol (1997) 15:617-648.
2. Lundholm P, Leandersson AC, Christensson B, Bratt G, Sandstrom E, Wahren B: DNA mucosal vaccine in humans. Virus Res (2002) 82(1-2):141-145.
3. Oh YK, Kim JP, Hwang TS, Ko JJ, Kim JM, Yang JS, Kim CK: Nasal adsorption and biodistribution of plasmid DNA: An alternative route of DNA vaccine delivery. Vaccine (2001) 19(31):4519-4525.
4. Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF: Experience with registered mucosal vaccines. Vaccine (2003) 21(7-8):678-683.
5. Matzinger P: The danger model: A renewed sense of self. Science (2002) 296(5566):301-305.
6. Gallucci S, Lolkema M, Matzinger P: Natural adjuvants: Endogenous activators of dendritic cells. Nat Med (1999) 5(11):1249-1255.
7. Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA: An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA (2000) 97(10):5492-5497.
8. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Siletti S, Lode HN, Dolman CS, Reisfeld RA: A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T-cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol (2001) 167(8):4560-4565.
9. Xiang R, SilLetti S, Lode HN, Dolman CS, Ruehlmann JM, Niethammer AG, Pertl U, Gillies SD, Primus FJ, Reisfeld RA: Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res (2001) 7(Suppl 3):S856-S864.
10. Niethammer AG, Primus FJ, Xiang R, Dolman CS, Ruehlmann JM, Ba Y, Gillies SD, Reisfeld RA: An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine (2002) 20(3-4):421-429.
11. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP: Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood (1998) 92(9):3172-3176.
12. Darji A, zur Lage S, Garbe AI, Chakraborty T, Weiss S: Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol (2000) 27(4):341-349.
13. Weiss S, Krusch S: Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells. Biol Chem (2001) 382(4):533-541.
14. Cossart P, Pizarro-Cerda J, Lecuit M. Invasion of mammalian cells by Listeria monocytogenes: Functional mimicry to subvert cellular functions. Trends Cell Biol (2003) 13(1):23-31.
15. Sizemore DR, Branstrom AA, Sadoff JC: Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (1995) 270(5234):299-302.
16. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR: Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol (1999) 162(3):1603-1610.
17. Anderson RJ, Pasetti MF, Sztein MB, Levine MM, Noriega FR: ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Vaccine (2000) 18(21):2193-2202.
18. Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB: Attenuated ΔguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol (1999) 92(1):76-89.
19. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S: Oral somatic transgene vaccination using attenuated S. typhimurium. Cell (1997) 91(6):765-775.
20. Powell RJ, Lewis GK, Hone DM: Introduction of eukaryotic expression cassettes into animal cells using bacterial vector delivery system. In: Vaccines 96: Molecular Approaches to the Control of Infectious Disease. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (1996):183-187.
21. Dietrich G, Bubert A, Gentschev I, Sokolovic Z, Simm A, Catic A, Kaufmann SH, Hess J, Szalay AA, Goebel W: Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol (1998) 16(2):181-185.
22. Hense M, Domann E, Krusch S, Wacholz P, Dittmar KE, Rohde M, Wehland J, Chakraborty T, Weiss S: Eukaryotic expression plasmid transfer from the intracellular bacterium Listeria monocytogenes to host cells. Cell Microbiol (2001) 3(9):599-609.
23. Dietrich G, Kolb-Mäurer A, Spreng S, Schartl M, Goebel W, Gentschev I: Gram-positive and Gram-negative bacteria as carrier systems for DNA vaccines. Vaccine (2001) 19(17-19):2506-2512.
24. Jain V, Mekalanos JJ: Use of the λ phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella enterica serovar Typhimurium-based DNA vaccine delivery systems. Infect Immun (2000) 68(2):986-989.
25. Grillot-Courvalin C, Goussard S, Courvalin P: Wild-type bacteria deliver DNA into mammalian cells. Cell Microbiol (2002) 4(3):177-186.
26. Courvalin P, Goussard S, Grillot-Courvalin C: Gene transfer from bacteria to mammalian cells. CR Acad Sci III (1995) 318(12):1201-1212.
27. Grillot-Courvalin C, Goussard S, Huetz F, Ojcius DM, Courvalin P: Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol (1998) 16(9):862-866.
28. Catic A, Dietrich G, Gentschev I, Goebel W, Kaufmann SH, Hess J: Introduction of protein or DNA delivered via recombinant Salmonella typhimurium into the major histocompatibility complex class I presentation pathway of macrophages. Microbes Infect (1999) 1(2):113-121.
29. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol (1999) 1(6):362-368.
30. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C: Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity (1995) 3(6):783-791.
31. Kunik T, Tzfira T, Kapulnik Y, Gafni Y, Dingwall C, Citovsky V: Genetic transformation of HeLa cells by Agrobacterium. Proc Natl Acad Sci USA (2001) 98(4):1871-1876.
32. Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson JJ: Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun (2002) 70(4):1915-1923.
33. Brunham RC, Zhang DJ: Transgene as vaccine for Chlamydia. Am Heart J (1999) 138(5 Pt 2):S519-S522.
34. Fló J, Tisminetzky S, Baralle F: Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent herpes simplex virus-2 induced disease in mice. Vaccine (2001) 19(13-14):1772-1782.
35. Elias F, Fló J: Modulation of the immune response by oral transgene administration of IL-10. Cell Immunol (2002) 216(1-2):73-81.
36. Woo PC, Wong LP, Zheng BJ, Yuen KY: Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine (2001) 19(20-22):2945-2954.
37. Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B: Oral Immunization with HVC-NS3-transformed Salmonella: Induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology (2001) 121(5):1158-1166.
38. Shata MT, Hone DM: Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T-cells and antiviral protective immunity. J Virol (2001) 75(20):9665-9670.
39. Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM: Mucosal and systemic HIV-1 specific CD8+ T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine (2002) 20(3-4):623-629.
40. Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ: Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T-cells against HIV. Immunol Lett (2002) 82(3):197-204.
41. Xu F, Hong M, Ulmer JB: Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine (2003) 21(7-8):644-648.
42. DeVico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM: Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine (2002) 20(15):1968-1974.
43. Shiau AL, Chen YL, Liao CY, Huang YS, Wu CL: Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella cholerasuis. Vaccine (2001) 19(28-29):3947-3956.
44. Wong LP, Woo PC, Wu AY, Yuen KY: DNA immunization using a secreted cell wall antigen Mp1p is protective against Penicillium marneffei infection. Vaccine (2002) 20(23-24):2878-2886.
45. Zheng LM, Luo X, Feng M, Li Z, Le T, Ittensohn M, Trailsmith M, Bermudes D, Lin SL, King IC: Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol Res (2000) 12(3):127-135.
46. Surh CD, Sprent J: Homeostatic T-cell proliferation: How far can T-cells be activated to self-ligands? J Exp Med (2000) 192(4):F9-F14.
47. Zöller M, Christ O: Prophylactic tumor vaccination: Comparison of effector mechanisms initiated by protein versus DNA vaccination. J Immunol (2001) 166(5):3440-3450.
48. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA: Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res (2001) 61(16):6178-6184.
49. Weth R, Christ O, Stevanovic S, Zöller M: Gene delivery by attenuated Salmonella typhimurium: Comparing the efficacy of helper versus cytotoxic T-cell priming in tumor vaccination. Cancer Gene Ther (2001) 8(8):599-611.
50. Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ: Oral DNA vaccination: Antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol Lett (2002) 80(2):89-96.
51. Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA: Tyrosine hydroxylase-based DNA vaccination is effective against murine neuroblastoma. Med Pediatr Oncol (2000) 35(6):641-646.
52. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA: Immunotherapy with a post-transcriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood (2003) 101(2):649-654.
53. Urashima M, Suzuki H, Yuza Y, Akiyama M, Ohno N, Eto Y: An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood (2000) 95(4):1258-1263.
54. Rosenkranz CD, Chiara D, Agorio C, Baz A, Pasetti MF, Schreiber F, Dematteis S, Martinez M, Sztein MB, Chabalgoity JA: Towards new immunotherapies: Targeting recombinant cytokines to the immune system using live attenuated Salmonella. Vaccine (2003) 21(7-8):798-801.
55. Yuhua L, Kunyuan G, Hui C, Yongmei X, Chaoyang S, Xun T, Daming R: Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer (2001) 94(3):438-443.
56. Paglia P, Terrazzini N, Schulze K, Guzman CA, Colombo MP: In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Ther (2000) 7(20):1725-1730.
57. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 8(12):1369-1375.
58. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Pickard D, Dougan G, Chatfield SN, Levine MM: Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 65(2):452-456.
59. VanCott JL, Chatfield SN, Roberts M, Hone DM, Hohmann EL, Pascual DW, Yamamoto M, Kiyono H, McGhee JR: Regulation of host immune responses by modification of Salmonella virulence genes. Nat Med (1998) 4(11):1247-1252.
60. Medina E, Paglia P, Nikolaus T, Muller A, Hensel M, Guzman CA: Pathogenicity island 2 mutants of Salmonella typhimurium are efficient carriers for heterologous antigens and enable modulation of immune responses. Infect Immun (1999) 67(3):1093-1099.
61. Favre D, Struck MM, Cryz SJ Jr, Viret JF: Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR. Vaccine (1996) 14(6):526-531.
62. Kaper JB, Michalski J, Ketley JM, Levine MM: Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR. Infect Immun (1994) 62(4):1480-1483.
63. Cichutek K: DNA vaccines: Development, standardization and regulation. Intervirology (2000) 43(4-6):331-338.
64. Butler VA: Points to consider on plasmid DNA vaccines for preventive infectious disease indications. FDA, CBER (1996) 61 FR 68269, docket No96N-0400.
65. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP): Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products. EMEA CPMP/BWP/3088/99 (2001).
66. Robertson JS, Griffiths E: Assuring the quality, safety, and efficacy of DNA vaccines. Mol Biotechnol (2001) 17(2):143-149.
67. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG 2nd, Harper LB, Schock HB, Zhang H, Faris JE, Way PA et al: Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev Biol (2000) 104:33-43.